Cardiovascular complications are a primary cause of premature mortality in acromegaly patients, responsible for around 60% of deaths [4], though biochemical control of the disease (normalization of GH and IGF-I levels) reduces mortality to that observed in the general population [5,6,7]. This evidence concerns the gene GH1 and acromegaly.